IP Library Granted Patent US 8,198,404
Granted Patent B2
US 8,198,404 · App. 12/900,958 · Granted Jun 12, 2012

Mutated immunoglobulin-binding protein

Assignee: GE Healthcare Bio-Sciences AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,198,404
App. No.
12/900,958
Granted
Jun 12, 2012
Kind
B2
Abstract

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (7)

1. In an immunoglobulin-binding protein having an amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 2 capable of binding to regions of the immunoglobulin molecule other than complementarity determining regions (CDR), the improvement comprising mutating at least one asparagine residue of a parental, or a functional variant thereof, with an amino acid other than glutamine, wherein the mutation(s) are selected from the group consisting of N23T and N3A; N23T and N3A and N6D; and N23T and N43E.

2. The protein of claim 1 , which is an Fc fragment-binding protein.

3. A multimer comprised of two or more mutated protein units of claim 1 .

4. The multimer of claim 3 , wherein the protein units are linked by elements including up to about 15 amino acids.

5. The multimer of claim 3 , further comprising one or more of the E, D, A, B, and C domains of Staphylococcus protein A.

6. The multimer of claim 3 , comprising three mutated protein units.

7. The multimer of claim 6 , wherein the protein unit is the protein defined by SEQ ID NO. 2 and includes the mutation N23T.

Assignments (4)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2010
From: HOBER, SOPHIA
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 025115/0285 →
CHANGE OF NAME Recorded Oct 8, 2010
From: AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 025115/0311 →
Priority Claims (1)
SE 0200943 · Mar 25, 2002 · national
Continuity (2)
Continuation 10508625
Related Publication 20110112276A1 · May 12, 2011